Hemab Therapeutics (NASDAQ:COAG) Research Coverage Started at JPMorgan Chase & Co.

JPMorgan Chase & Co. assumed coverage on shares of Hemab Therapeutics (NASDAQ:COAG) in a report released on Thursday, Marketbeat reports. The brokerage issued an overweight rating and a $70.00 price target on the stock.

Several other equities research analysts also recently weighed in on the stock. Jefferies Financial Group raised their target price on shares of Hemab Therapeutics from $39.00 to $47.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Wedbush lifted their price target on shares of Hemab Therapeutics from $55.00 to $64.00 and gave the stock an “outperform” rating in a report on Wednesday, August 12th. Rodman & Renshaw began coverage on Hemab Therapeutics in a research report on Monday, October 12th. They set a “buy” rating and a $56.00 price target on the stock. HC Wainwright increased their price objective on Hemab Therapeutics from $52.00 to $60.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. Finally, Weiss Ratings lowered Hemab Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, September 25th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Hemab Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $54.71.

Hemab Therapeutics Trading Down 7.5%

COAG stock opened at $30.07 on Thursday. The stock has a market capitalization of $1.40 billion and a price-to-earnings ratio of -1.21. The firm’s 50-day moving average price is $40.88. Hemab Therapeutics has a one year low of $23.00 and a one year high of $55.42.

Hemab Therapeutics (NASDAQ:COAG) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.17). As a group, sell-side analysts expect that Hemab Therapeutics will post -3.10 EPS for the current year.

Hedge Funds Weigh In On Hemab Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. State Street Corp acquired a new position in Hemab Therapeutics during the 2nd quarter valued at approximately $2,825,000. Opaleye Management Inc. purchased a new position in shares of Hemab Therapeutics in the second quarter worth $1,750,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Hemab Therapeutics during the second quarter worth $688,000. Squarepoint Ops LLC acquired a new stake in shares of Hemab Therapeutics during the second quarter worth $230,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Hemab Therapeutics during the second quarter worth $19,226,000.

Hemab Therapeutics Company Profile

Hemab Therapeutics (NASDAQ: COAG) is a clinical-stage biopharmaceutical company developing treatments for serious and potentially life-threatening bleeding disorders. The company focuses on rare conditions for which existing therapies may be limited, inconvenient, or ineffective for some patients.

Hemab’s lead investigational program, HMB-001, is an engineered bispecific antibody designed to improve blood clotting by enhancing thrombin generation through inhibition of tissue factor pathway inhibitor.